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Since the beginning of the Coronavirus Infectious Disease 2019 (COVID-19)
pandemic, through an unprecedented global effort at vaccine development, currently
we have several emergency use authorization (EUA) vaccines available and
administered in US and throughout the world. Three major vaccine platforms/
technologies utilized to develop the currently available and administered vaccines.
These platforms are: mRNA-based vaccines, viral vectored-based vaccines and
protein-based vaccines.
Usually, it takes about 10 years to complete research and development, clinical trial
and gain FDA approval for a typical vaccine. But COVID-19 vaccine development
broke all records, from the beginning through end everything have been accomplished
within a year. Therefore, although it may seemed rushed, every possible scientific
stringency, regulatory oversight and clinical safety have been closely monitored
leading to EUA of these vaccines.
In this presentation we will look into various COVID-19 vaccine platforms, immune
response and efficacy in clinical trial and vaccinated individuals with approval. We will
also analyze available information regarding vaccine efficacy/ protection against the
emergent COVID-19 variants of concern (VOC).
COVID-19 related keyword search and review of primary and tertiary literatures
available in medRxiv, PubMed, CDC and NIAID database was employed. The search
specifically focused on Covid-19 vaccine clinical trial data and vaccine-induced
immune protection against infection.
The purpose of this presentation is to provide an overview of the various vaccines 
formulations for coronavirus infectious disease 2019 (COVID-19). We will discuss 
various technology platforms used for rapid development of the vaccines, types of 
immune response generated, efficacy and vaccine-induced immune protection 






Fig 2. SARS-CoV-2 Life Cycle and Structure 
Important for Vaccine and Drug Development.
Fig 6. Proposed Mechanisms of Vaccine-
induced Immune Response
Fig 3. The Trinity of COVID-19: Immunity, 
Inflammation and Intervention
Fig 5.  COVID-19 Vaccine Platforms.
Fig 4. COVID-19 Vaccine Development Timeline 
Compared to Traditional Vaccines .
COVID-19 Vaccine Formulations
 mRNA-based: Moderna, Pfizer-BioNTech
 S-protein mRNA in lipid nanoparticle formulation
 Viral vector-based: genetically engineered virus with ‘S protein’ DNA 
 Adenovirus: AstraZeneca, Johnson & Johnson ( J & J) , Gamaleya, CanSino 
Biologics
 Protein-based vaccines: 
 Novavax, PittcoVac -S protein specific
 DNA vaccine
 Inovio
 Killed virus vaccine
 Covaxin, Bharat Biotech, India
EM of a cell heavily infected with SARS-
COV-2 virus particles, isolated from a 
patient sample. NIAID.
Fig 1. SARS-CoV-2 Structure, and Cell Infected with the Viral Particles.
Safety and Efficacy of COVID-19 Vaccines
 All three vaccines Moderna, Pfizer and J & J are safe with minimum adverse 
reactions
 Pfizer and Moderna vaccines work  in population with 90% effective at preventing 
infection, including asymptomatic infection
 These vaccines generated robust, neutralizing & long-lasting Ab lasting over >6 
months, & protection could last up to 2 years
 These vaccines also generated T cell responses important in clearing of the virus 
infection
 Pfizer Vaccine generated antibody response in pregnant and lactating women, 
and well-tolerated
 Pfizer vaccine is also safe and effective in young adolescents
 Pfizer, J & J and Moderna vaccines are protective against the emerging variants 
with varying degrees
 Both Pfizer and J & J vaccine effective against S. African and UK variant
COVID-19 Vaccine Schedules
 Pfizer/BioNtech: 2 shots 21d apart, 95% protection 
 Moderna: 2 shots 28d apart, 94% protection
 Johnson & Johnson: 1 shot, 85% efficacy against severe infection 
 AstraZeneca: 2 shots, 28d apart, ~70 (60-90)% efficacy
 Sputnik V: 2-dose 28d apart, 95% efficacy
 Covaxin-killed virus vaccine, Bharat Biotech & ICMR, 2 doses 14d apart
Fig 6.  Relationship Between  Vaccine Development, Vaccine 
Acceptance and Infection
 Several effective, and well-tolerated COVID-19 vaccines have been 
developed in a record time.
 The vaccine technology platform ranges from lipid nanoparticle-mRNA, 
adenoviral vector-mediated, protein vaccine and killed virus vaccine.
 All the vaccine formulations target ‘S’ protein, ligand for ACE2 receptor,  
critically important for blocking the infection. 
 Vaccines induced robust and protective immune responses in  wide age 
group individuals, and ethnicity.
 Vaccines confer significant protection against both asymptomatic, and 
severe infection, thus preventing hospitalization and death. 
 Vaccine-induced immunity includes both B and T cell responses with 
memory function for long-term protection.
 Early results indicate that these vaccines also confer significant 
protection against the emerging variants.
 Even with available effective vaccines against COVID-19, ‘vaccine 
hesitancy’ in US and around the world remains as a concern for 
achieving ‘herd immunity’ for defeating the pandemic.
